ADC Therapeutics SA, a leader in antibody drug conjugates, has announced the granting of options to purchase 127,000 common shares to three new employees as part of an inducement plan. Approved by the Board's Compensation Committee, these grants are intended to be significant incentives for new hires. The options will vest at 25% after one year and continue monthly over four years, contingent on ongoing employment. This announcement aligns with NYSE's rules for employment inducement exemptions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.